Daniel M. Halperin

7.3k total citations · 2 hit papers
102 papers, 4.2k citations indexed

About

Daniel M. Halperin is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Daniel M. Halperin has authored 102 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Epidemiology, 78 papers in Oncology and 60 papers in Neurology. Recurrent topics in Daniel M. Halperin's work include Neuroendocrine Tumor Research Advances (77 papers), Lung Cancer Research Studies (63 papers) and Neuroblastoma Research and Treatments (59 papers). Daniel M. Halperin is often cited by papers focused on Neuroendocrine Tumor Research Advances (77 papers), Lung Cancer Research Studies (63 papers) and Neuroblastoma Research and Treatments (59 papers). Daniel M. Halperin collaborates with scholars based in United States, Canada and United Kingdom. Daniel M. Halperin's co-authors include James C. Yao, Arvind Dasari, Chan Shen, Ya‐Chen Tina Shih, Shouhao Zhou, Ying Xu, Bo Zhao, Mahendar Ochani, Runkuan Yang and Kevin J. Tracey and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel M. Halperin

97 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

2017 2.3k citations Arvind Dasari, Chan Shen et al. profile →
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation

2002 510 citations Daniel M. Halperin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel M. Halperin United States	20	3.4k	3.1k	2.1k	305	284	102	4.2k
Catharina M. Korse Netherlands	32	1.1k 0.3×	1.3k 0.4×	744 0.4×	209 0.7×	215 0.8×	88	2.8k
Lowell Anthony United States	34	3.8k 1.1×	3.7k 1.2×	2.7k 1.3×	347 1.1×	60 0.2×	175	5.0k
Roberto Buzzoni Italy	33	1.3k 0.4×	2.5k 0.8×	937 0.4×	474 1.6×	164 0.6×	165	3.7k
Rebecca A. Moss United States	24	490 0.1×	4.0k 1.3×	245 0.1×	890 2.9×	959 3.4×	74	5.5k
Florencia G. Que United States	42	2.1k 0.6×	3.3k 1.1×	1.1k 0.5×	2.6k 8.7×	54 0.2×	105	5.5k
Sven Hoffmeyer Germany	14	225 0.1×	2.4k 0.8×	392 0.2×	402 1.3×	64 0.2×	19	3.6k
Cosimo Sperti Italy	35	1.2k 0.3×	3.3k 1.0×	158 0.1×	1.9k 6.3×	202 0.7×	141	4.1k
Horst Schran United States	28	337 0.1×	1.1k 0.4×	173 0.1×	268 0.9×	117 0.4×	70	3.0k
Nicoletta Zilembo Italy	29	807 0.2×	2.1k 0.7×	488 0.2×	190 0.6×	133 0.5×	113	3.2k
Richard M. Green United States	26	1.0k 0.3×	508 0.2×	124 0.1×	729 2.4×	75 0.3×	64	2.7k

Countries citing papers authored by Daniel M. Halperin

Since Specialization

Citations

This map shows the geographic impact of Daniel M. Halperin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel M. Halperin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel M. Halperin more than expected).

Fields of papers citing papers by Daniel M. Halperin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel M. Halperin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel M. Halperin. The network helps show where Daniel M. Halperin may publish in the future.

Co-authorship network of co-authors of Daniel M. Halperin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel M. Halperin. A scholar is included among the top collaborators of Daniel M. Halperin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel M. Halperin. Daniel M. Halperin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morris, Van K., Suyu Liu, Kangyu Lin, et al.. (2025). Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clinical Cancer Research. 31(9). 1657–1666. 1 indexed citations

Halperin, Daniel M., Sten Myrehaug, Pamela L. Kunz, et al.. (2024). 211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study. Annals of Oncology. 35. S92–S93. 4 indexed citations

Dasari, Arvind, et al.. (2024). Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine Related Cancer. 31(4). 8 indexed citations

Ghosh, Sukhen C., et al.. (2024). Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide. Journal of Medicinal Chemistry. 67(4). 2425–2437. 4 indexed citations

Hornstein, Nicholas J., Mohammad A. Zeineddine, Andrew J. Pellatt, et al.. (2024). Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Research Communications. 4(5). 1363–1368. 3 indexed citations

Meng, Qing H., Þorvarður R. Hálfdánarson, Joshua A. Bornhorst, et al.. (2024). Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids—The CASPAR Study. Clinical Cancer Research. 30(24). 5559–5567. 1 indexed citations

Morris, Van K., Haifeng Zhu, Xiaoling Li, et al.. (2023). P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer. Annals of Oncology. 34. S97–S97. 1 indexed citations

Hálfdánarson, Þorvarður R., Jaume Capdevila, Daniel M. Halperin, et al.. (2023). Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.. Journal of Clinical Oncology. 41(4_suppl). TPS660–TPS660.

Figueroa, Rocío, Alexandros Rampotas, Daniel M. Halperin, et al.. (2023). Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study. British Journal of Haematology. 202(1). 48–53. 6 indexed citations

10.

Perez, Kimberly, Heather A. Jacene, Jason L. Hornick, et al.. (2022). SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocrine Related Cancer. 29(9). 533–544. 9 indexed citations

11.

Ghosh, Sukhen C., Michael Luciano, Po Hien Ear, et al.. (2022). High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Molecular Pharmaceutics. 19(11). 4241–4253. 12 indexed citations

12.

Kadakia, Kushal T., Daniel M. Halperin, & Anaeze C. Offodile. (2021). Operationalizing Virtual Trials in Oncology—From Aspiration to Action. JCO Clinical Cancer Informatics. 5(5). 953–957. 4 indexed citations

13.

Rogers, Jane E., Michael Lam, Daniel M. Halperin, et al.. (2021). Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 112(1). 34–42. 12 indexed citations

14.

Pan, I‐Wen, et al.. (2021). A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. PharmacoEconomics. 39(11). 1271–1297. 2 indexed citations

15.

Shaunfield, Sara, Kimberly Webster, Karen Kaiser, et al.. (2020). Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 111(9). 850–862. 4 indexed citations

16.

Abu‐Sbeih, Hamzah, Niharika Mallepally, Tenglong Tang, et al.. (2020). Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. Journal of Cancer. 11(11). 3144–3150. 14 indexed citations

17.

Dasari, Arvind, et al.. (2019). PCN113 DIRECT AND INDIRECT COSTS ASSOCIATED WITH CARCINOID SYNDROME DIARRHEA. Value in Health. 22. S77–S77. 1 indexed citations

18.

Shen, Chan, Arvind Dasari, Ying Xu, et al.. (2018). Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Scientific Reports. 8(1). 16863–16863. 13 indexed citations

19.

Raghav, Kanwal, et al.. (2018). Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Medical Research Methodology. 18(1). 169–169. 7 indexed citations

20.

Halperin, Daniel M., et al.. (2011). Land resource requirements for bioenergy in India. Journal of Scientific & Industrial Research. 70(8). 721–726. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact